<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408965</url>
  </required_header>
  <id_info>
    <org_study_id>UP Trial 2015</org_study_id>
    <nct_id>NCT02408965</nct_id>
  </id_info>
  <brief_title>Uterotonic Prophylaxis Trial</brief_title>
  <acronym>UPT</acronym>
  <official_title>A Randomized Controlled Trial of Methylergonovine Prophylaxis After Dilation and Evacuation Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excessive bleeding after dilation and evacuation (D&amp;E) requiring interventions is common,
      occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic
      prophylaxis at the time of D&amp;E, particularly with methylergonovine maleate (MM), is a common
      practice among D&amp;E providers despite nearly no evidence for its efficacy. Finding ways to
      decrease excessive bleeding after D&amp;E has the potential both to improve patient safety and to
      reduce costs of provider-initiated interventions. The investigators propose a randomized,
      controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing
      excessive bleeding measured by a composite outcome among women undergoing D&amp;E at 20 to 24
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Excessive Bleeding as Determined by the Composite Outcome Criteria</measure>
    <time_frame>Approximately 1-2 hours after procedure</time_frame>
    <description>Clinical factors included in composite outcome of excessive bleeding after D&amp;E:
Post-procedure total blood loss &gt; 125cc (after D&amp;E) Transfusion Admission for bleeding Re-aspiration for bleeding Balloon tamponade Uterine artery embolization Major surgery for bleeding At least 1 uterotonic medication given Prescription given for any uterotonic medication at discharge Uterine compression (uterine massage or manual pressure for 2 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Post-procedure Blood Loss Measured in mL</measure>
    <time_frame>measured 1 to 2 hours after procedure</time_frame>
    <description>post-procedure blood loss measured in recovery room</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Had a Balloon Tamponade Placed From Start of Procedure to Hospital Discharge</measure>
    <time_frame>duration of procedure and until discharged from hospital</time_frame>
    <description>number of participants who had a balloon tamponade placed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Returned to OR for Re-aspiration During Recovery Period</measure>
    <time_frame>from cervical preparation through discharge</time_frame>
    <description>Returned to OR for re-aspiration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Admitted for Bleeding After Procedure</measure>
    <time_frame>post-procedure and during recovery until discharge</time_frame>
    <description>hospital admission for bleeding post-procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Given Any Uterotonic</measure>
    <time_frame>intra-operative or post-operative until discharge</time_frame>
    <description>any uterotonic medication given intraoperative or postoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Nausea up to One Hour After Procedure</measure>
    <time_frame>Assessed approximately 1 hour after procedure</time_frame>
    <description>Patients' completed survey regarding side effects in recovery room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reported Vomiting up to One Hour After Procedure</measure>
    <time_frame>Assessed approximately 1 hour after procedure</time_frame>
    <description>Patients' completed survey regarding side effects in recovery room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Cramping up to One Hour After Procedure</measure>
    <time_frame>Assessed approximately 1 hour after procedure</time_frame>
    <description>Patients' completed survey regarding side effects in recovery room.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>methergine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group saline single injection when manual cervical dilation begins the day before the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methergine</intervention_name>
    <description>0.2 mg of methylergonovine maleate</description>
    <arm_group_label>methergine</arm_group_label>
    <other_name>methylergonovine maleate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline placebo to maintain blinding</description>
    <arm_group_label>saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 20 wks 0 days gestation and 24 wks 0 days gestation

          -  English or Spanish speaking

          -  BP before injection 140/90 or below

          -  18 years old or over

        Exclusion criteria:

          -  hypertension either on the preoperative or operative day (defined as systolic blood
             pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg)

          -  D&amp;E procedures with more than one day of cervical preparation with dilators

          -  use of protease inhibitors

          -  known coagulopathy

          -  known morbidly adherent placenta
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Kerns, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFGH Women's Options Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <results_first_submitted>May 9, 2018</results_first_submitted>
  <results_first_submitted_qc>August 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylergonovine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02408965/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02408965/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Determined ineligible (n=28) Patient withdrew (n=6) Administrative error (n=2)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methergine</title>
          <description>Methergine group</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methergine</title>
          <description>Methergine group</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="284"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" lower_limit="21" upper_limit="29"/>
                    <measurement group_id="B2" value="25" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="B3" value="24.8" lower_limit="21" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" lower_limit="23" upper_limit="31"/>
                    <measurement group_id="B2" value="26" lower_limit="23" upper_limit="29"/>
                    <measurement group_id="B3" value="26.3" lower_limit="23" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nulliparous</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior cesarean section</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestation</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.6" lower_limit="21" upper_limit="23"/>
                    <measurement group_id="B2" value="21.5" lower_limit="20" upper_limit="23"/>
                    <measurement group_id="B3" value="21.6" lower_limit="20" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Needed mechanical dilation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of procedure</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="8" upper_limit="16"/>
                    <measurement group_id="B2" value="12" lower_limit="9" upper_limit="15"/>
                    <measurement group_id="B3" value="12" lower_limit="8" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Procedural measured blood loss</title>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300" lower_limit="150" upper_limit="400"/>
                    <measurement group_id="B2" value="250" lower_limit="150" upper_limit="425"/>
                    <measurement group_id="B3" value="275" lower_limit="150" upper_limit="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current or recent cocaine or methamphetamine use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of bleeding disorder</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative systolic BP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112" spread="11"/>
                    <measurement group_id="B2" value="112" spread="10"/>
                    <measurement group_id="B3" value="112" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative diastolic BP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9"/>
                    <measurement group_id="B2" value="69" spread="8"/>
                    <measurement group_id="B3" value="69" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Excessive Bleeding as Determined by the Composite Outcome Criteria</title>
        <description>Clinical factors included in composite outcome of excessive bleeding after D&amp;E:
Post-procedure total blood loss &gt; 125cc (after D&amp;E) Transfusion Admission for bleeding Re-aspiration for bleeding Balloon tamponade Uterine artery embolization Major surgery for bleeding At least 1 uterotonic medication given Prescription given for any uterotonic medication at discharge Uterine compression (uterine massage or manual pressure for 2 minutes</description>
        <time_frame>Approximately 1-2 hours after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Excessive Bleeding as Determined by the Composite Outcome Criteria</title>
          <description>Clinical factors included in composite outcome of excessive bleeding after D&amp;E:
Post-procedure total blood loss &gt; 125cc (after D&amp;E) Transfusion Admission for bleeding Re-aspiration for bleeding Balloon tamponade Uterine artery embolization Major surgery for bleeding At least 1 uterotonic medication given Prescription given for any uterotonic medication at discharge Uterine compression (uterine massage or manual pressure for 2 minutes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Post-procedure Blood Loss Measured in mL</title>
        <description>post-procedure blood loss measured in recovery room</description>
        <time_frame>measured 1 to 2 hours after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Post-procedure Blood Loss Measured in mL</title>
          <description>post-procedure blood loss measured in recovery room</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="86" upper_limit="166"/>
                    <measurement group_id="O2" value="76" lower_limit="65" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had a Balloon Tamponade Placed From Start of Procedure to Hospital Discharge</title>
        <description>number of participants who had a balloon tamponade placed</description>
        <time_frame>duration of procedure and until discharged from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Balloon Tamponade Placed From Start of Procedure to Hospital Discharge</title>
          <description>number of participants who had a balloon tamponade placed</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Returned to OR for Re-aspiration During Recovery Period</title>
        <description>Returned to OR for re-aspiration</description>
        <time_frame>from cervical preparation through discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Returned to OR for Re-aspiration During Recovery Period</title>
          <description>Returned to OR for re-aspiration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Admitted for Bleeding After Procedure</title>
        <description>hospital admission for bleeding post-procedure</description>
        <time_frame>post-procedure and during recovery until discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Admitted for Bleeding After Procedure</title>
          <description>hospital admission for bleeding post-procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Given Any Uterotonic</title>
        <description>any uterotonic medication given intraoperative or postoperative</description>
        <time_frame>intra-operative or post-operative until discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Given Any Uterotonic</title>
          <description>any uterotonic medication given intraoperative or postoperative</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Nausea up to One Hour After Procedure</title>
        <description>Patients' completed survey regarding side effects in recovery room.</description>
        <time_frame>Assessed approximately 1 hour after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Nausea up to One Hour After Procedure</title>
          <description>Patients' completed survey regarding side effects in recovery room.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reported Vomiting up to One Hour After Procedure</title>
        <description>Patients' completed survey regarding side effects in recovery room.</description>
        <time_frame>Assessed approximately 1 hour after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported Vomiting up to One Hour After Procedure</title>
          <description>Patients' completed survey regarding side effects in recovery room.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Cramping up to One Hour After Procedure</title>
        <description>Patients' completed survey regarding side effects in recovery room.</description>
        <time_frame>Assessed approximately 1 hour after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methergine</title>
            <description>Methergine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Cramping up to One Hour After Procedure</title>
          <description>Patients' completed survey regarding side effects in recovery room.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, March 2015 to March 2017</time_frame>
      <desc>It took from March 2015 to March 2017 to meet the study sample size. Therefore, the timeframe March 2015 through March 2017 is the duration that adverse events were monitored/collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Methergine</title>
          <description>Methergine group</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>admission to hospital for bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balloon tamponade</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="140"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>reasperation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>transfusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>uterine artery embolization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Designed our study using a one-sided hypothesis given our belief that methergine could not cause increased bleeding based on postpartum data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer Kerns</name_or_title>
      <organization>UCSF</organization>
      <phone>4152068715</phone>
      <email>Jennifer.kerns@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

